A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma
In this study, we examined the anti-tumor effect of the antibody toxin conjugate (ADC) against activated matriptase positive mantle cell lymphoma cell lines (JeKo-1, Maver, Mino, and Z138). This ADC was cytotoxic to these cell lines with IC50s between 5 and 14 μg/mL. The ADC also showed a dose dependent anti-tumor effect on the JeKo-1 xenograft in mice without toxicity. Introduction Mantle Cell Lymphoma (MCL), represents 6- percent of all lymphoma cases, and currently the survival time is 4–5 years, shorter compared to other hematologic malignancies (2–4). MCL cells express CD20, aberrant expression of CD5, and due to a translocation t(11;14)(q13;q32), overexpression of cyclin-D1, encoded by the CCND1 gene located on chromosome 11, which mediates cell cycle progression through the G1 phase (5, 6). The currently used drugs to treat MCL patients include bortezomib, ibrutinib, rituximab, bendamustine, and combinations of these drugs. Matriptase, a glycoprotein (80–90 kDa), is a member of type II transmembrane serine proteases. It is synthesized as a latent single-chain structure and with many regulatory mechanisms and functions (7, 8), and is activated through an auto-activation step resulting in a disulfide-linked-two-chain structure. Following activation, matriptase is rapidly inactivated by its endogenous inhibitor HAI-1. This activated matriptase-HAI-1 complex remains present in most epithelial carcinomas and some B-cell malignancies (9–11...
We present a case report of an adult woman with AKL-positive ALCL, diagnosed by endobronchial ultrasound-guided transbronchial needle aspirate (EBUS-TBNA).A 59-year-old women with no history of breast implants, was admitted for a four-month low back pain. Initially, the patient was treated for a spondyloarthropathy, but due to persistence of the symptoms, a lumbosacral MRI was performed, showing changes in morphology and signal intensity in the vertebral body of L3, along with edema and a paravertebral collection that affected the left psoas muscle, suggesting granulomatous spondylodiscitis. Chest CT-scan showed mild left ...
Thousands of men across the world have participated in randomized clinical trials testing the role of hormone therapy in the curative treatment of localized, high-risk prostate cancer. Over several decades, we have established that long-term hormone therapy improves survival, even in the setting of dose-escalated external beam radiation therapy (EBRT).1 Recently reported clinical trials suggest that for some men 18 months of hormone therapy may be a suitable duration that balances treatment efficacy with quality-of-life preservation.
We welcome 3 new associate editors: Drs Christopher Anker (University of Vermont Larner College of Medicine), Michael Buckstein (Icahn School of Medicine at Mount Sinai), and Jordan Kharofa (University of Cincinnati College of Medicine), whom were selected for their timely and thoughtful critiques as Red Journal reviewers. Although all 3 reviewers are experts in gastrointestinal (GI) radiation oncology, Dr Anker provides expertise in esophageal and rectal cancers, Dr Buckstein in liver cancers and translational science, and Dr Kharofa in pancreatic and anal cancers.
To clarify the relative effects of duration of androgen suppression (AS) and radiation dose escalation (RDE) on distant progression (DP) in men with locally advanced prostate cancer.
We thank the authors1 for their letter highlighting the critical issues facing the feasibility and efficacy of stereotactic ablative radiation (SAbR) as a boost for patients with cervical cancer unable to receive standard brachytherapy.
We applaud the University of Texas Southwestern Department of Radiation Oncology for conducting “A phase II trial of stereotactic ablative radiotherapy as a boost for locally advanced cervical cancer,” a necessary prospective study on definitive dose delivery for patients unable to undergo brachytherapy.1 The involved trialists were undoubtedly deliberate and meticulous in its design and e xecution, akin to their groundbreaking work with lung stereotactic body radiation therapy (SBRT). Although these results unfortunately showed high rates of rectal toxicity, the data does not indicate a failure of SBRT, but ra...
A 58-year-old female presents with a 1-year history of hematochezia, 20-pound weight loss, and increased straining with bowel movements. She denies increased bowel frequency or change in stool caliber. Her medical history is notable for irritable bowel syndrome, but otherwise unremarkable. She has no family history of malignancy and does not take any prescribed medications or supplements. She denies abdominal pain, bone pain, or any symptoms concerning for metastatic disease. Her initial physical examination was notable for an Eastern Cooperative Oncology Group performance status of 0, and presence on digital rectal examin...
In Africa, there were over 846,000 new cancer cases and 591,000 deaths in 2012. These figures are projected to rise to 1.27 million cases and 0.97 million deaths annually by 20301 as a result of population growth and aging alone.
Authors: Fung KH, Tsang WK, Kwok PCH, Lee WT, Tang KW PMID: 32077862 [PubMed - in process]
Conclusions: The evidence suggests differential effects of extended postclosure antibiotic duration on SSI odds contingent on the degree of contamination in open fracture wounds. Although extended antibiotic duration resulted in lower odds of SSI among patients with severely contaminated wounds, we observed a trend toward higher odds of SSI in mildly contaminated wounds. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
More News: Academia | Baylor College of Medicine | Biotechnology | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemistry | Clinical Trials | Copper | Databases & Libraries | Drugs & Pharmacology | Environmental Health | Epithelial Cancer | Genetics | Gout | Grants | Hairy Cell Leukemia | Health and Safety | Hematology | Hodgkin's Disease | Immunotherapy | Kidney Cancer | Laboratory Medicine | Leukemia | Lymphoma | Medical Ethics | Merck | Milk | Prostate Cancer | Renal Cell Carcinoma | Reproduction Medicine | Rituxan | Skin | Statistics | Students | Study | Toxicology | Translocation | Treanda | Universities & Medical Training | Urology & Nephrology | USA Health | Velcade | Weight Loss